Anxiolytic properties of compounds that counteract oxidative stress, neuroinflammation, and glutamatergic dysfunction: a review.
Acetamides
/ pharmacology
Acetylcysteine
/ pharmacology
Animals
Anti-Anxiety Agents
/ pharmacology
Anxiety Disorders
/ drug therapy
Disease Models, Animal
Fatty Acids, Omega-3
/ pharmacology
Glutamine
/ drug effects
Humans
Hypnotics and Sedatives
/ pharmacology
Neuroimmunomodulation
/ drug effects
Oxidative Stress
/ drug effects
Journal
Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)
ISSN: 1809-452X
Titre abrégé: Braz J Psychiatry
Pays: Brazil
ID NLM: 100895975
Informations de publication
Date de publication:
Historique:
received:
25
09
2017
accepted:
31
01
2018
pubmed:
18
10
2018
medline:
21
6
2019
entrez:
18
10
2018
Statut:
ppublish
Résumé
Anxiety disorders are highly prevalent and the efficacy of the available anxiolytic drugs is less than desired. Adverse effects also compromise patient quality of life and adherence to treatment. Accumulating evidence shows that the pathophysiology of anxiety and related disorders is multifactorial, involving oxidative stress, neuroinflammation, and glutamatergic dysfunction. The aim of this review was to evaluate data from animal studies and clinical trials showing the anxiolytic effects of agents whose mechanisms of action target these multiple domains. The PubMed database was searched for multitarget agents that had been evaluated in animal models of anxiety, as well as randomized double-blind placebo-controlled clinical trials of anxiety and/or anxiety related disorders. The main multitarget agents that have shown consistent anxiolytic effects in various animal models of anxiety, as well in clinical trials, are agomelatine, N-acetylcysteine (NAC), and omega-3 fatty acids. Data from clinical trials are preliminary at best, but reveal good safety profiles and tolerance to adverse effects. Agomelatine, NAC and omega-3 fatty acids show beneficial effects in clinical conditions where mainstream treatments are ineffective. These three multitarget agents are considered promising candidates for innovative, effective, and better-tolerated anxiolytics.
Identifiants
pubmed: 30328963
pii: S1516-44462018005007109
doi: 10.1590/1516-4446-2018-0005
pmc: PMC6781690
pii:
doi:
Substances chimiques
Acetamides
0
Anti-Anxiety Agents
0
Fatty Acids, Omega-3
0
Hypnotics and Sedatives
0
Glutamine
0RH81L854J
agomelatine
137R1N49AD
Acetylcysteine
WYQ7N0BPYC
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
168-178Références
J Clin Pharm Ther. 2016 Apr;41(2):214-9
pubmed: 26931055
Brain Res. 2012 Jul 23;1466:91-8
pubmed: 22647752
Neurosci Biobehav Rev. 2015 Aug;55:294-321
pubmed: 25957927
J Clin Psychopharmacol. 2015 Jun;35(3):336-8
pubmed: 25856784
Clin Exp Ophthalmol. 2009 Mar;37(2):223-31
pubmed: 19723131
Neuropsychopharmacology. 2004 Mar;29(3):502-13
pubmed: 14694349
World J Biol Psychiatry. 2011 Dec;12(8):574-87
pubmed: 21999473
J Pharmacol Exp Ther. 2001 Oct;299(1):12-20
pubmed: 11561058
Curr Med Res Opin. 2011 Apr;27(4):745-9
pubmed: 21271795
CNS Drugs. 2015 Sep;29(9):801-9
pubmed: 26374743
Pharmacol Biochem Behav. 2011 Jan;97(3):494-9
pubmed: 21036190
Arch Gen Psychiatry. 2009 Jul;66(7):756-63
pubmed: 19581567
Trends Pharmacol Sci. 2013 Mar;34(3):167-77
pubmed: 23369637
J Affect Disord. 2017 Dec 15;224:27-31
pubmed: 27287561
Am J Psychiatry. 2012 Nov;169(11):1143-9
pubmed: 23128921
Int J Trichology. 2012 Jul;4(3):176-8
pubmed: 23180931
J Clin Psychiatry. 2010 Feb;71(2):109-20
pubmed: 20193645
Pak J Biol Sci. 2015 Jan;18(1):11-8
pubmed: 26353411
J Lipid Res. 2015 Aug;56(8):1511-8
pubmed: 26063461
Nat Neurosci. 2007 Nov;10(11):1387-94
pubmed: 17965659
Eur Neuropsychopharmacol. 2017 May;27(5):526-537
pubmed: 28298261
J Affect Disord. 2013 Sep 25;150(3):829-33
pubmed: 23706841
Int J Neuropsychopharmacol. 2007 Oct;10(5):661-73
pubmed: 17477888
Int Clin Psychopharmacol. 2010 Nov;25(6):305-14
pubmed: 20856123
Neurotoxicology. 2007 Nov;28(6):1191-9
pubmed: 17727954
Psychopharmacology (Berl). 2011 Oct;217(3):301-13
pubmed: 21503609
Nat Neurosci. 2015 Oct;18(10):1394-404
pubmed: 26404714
Physiol Behav. 1994 Sep;56(3):609-17
pubmed: 7972416
Nat Rev Drug Discov. 2005 Feb;4(2):131-44
pubmed: 15665858
J Pharmacol Sci. 2012;119(1):97-101
pubmed: 22510519
Eur Psychiatry. 2008 Sep;23(6):396-402
pubmed: 18583104
CNS Neurol Disord Drug Targets. 2011 Feb;10(1):119-32
pubmed: 20874703
PLoS One. 2011;6(6):e20491
pubmed: 21666750
J Clin Psychiatry. 2012 Jul;73(7):1002-8
pubmed: 22901350
Front Behav Neurosci. 2014 Jun 17;8:219
pubmed: 24987341
J Clin Psychiatry. 2013 Jul;74(7):732-8
pubmed: 23945451
Hum Psychopharmacol. 2013 Mar;28(2):151-9
pubmed: 23532747
Behav Brain Funct. 2013 Jun 14;9:25
pubmed: 23768007
Nat Chem Biol. 2008 Nov;4(11):682-90
pubmed: 18936753
Physiol Behav. 1998 Feb 15;63(4):571-6
pubmed: 9523900
Physiol Behav. 2011 Sep 1;104(3):365-72
pubmed: 21515294
J Clin Psychopharmacol. 2007 Apr;27(2):227-9
pubmed: 17414258
Neuropsychiatr Dis Treat. 2015 May 05;11:1149-55
pubmed: 25999720
J Psychiatr Res. 2004 May-Jun;38(3):323-5
pubmed: 15003438
Prostaglandins Leukot Essent Fatty Acids. 2010 Apr-Jun;82(4-6):295-303
pubmed: 20227866
Brain Behav Immun. 2011 Nov;25(8):1725-34
pubmed: 21784145
Prog Neuropsychopharmacol Biol Psychiatry. 2006 Aug 30;30(6):1039-42
pubmed: 16682105
Neurosci Biobehav Rev. 2007;31(1):89-102
pubmed: 16934871
Neuropsychobiology. 2010;61(4):210-4
pubmed: 20389131
Eur Arch Psychiatry Clin Neurosci. 2004 Aug;254(4):231-5
pubmed: 15309392
Behav Pharmacol. 2006 Feb;17(1):9-18
pubmed: 16377959
Br J Pharmacol. 2011 Oct;164(4):1129-61
pubmed: 21545412
Neuropsychobiology. 2002;46(4):186-9
pubmed: 12566935
Mediators Inflamm. 2008;2008:716458
pubmed: 18483565
J Clin Psychopharmacol. 2008 Oct;28(5):561-6
pubmed: 18794654
BMC Neurosci. 2010 Jun 03;11:68
pubmed: 20525261
Free Radic Res. 2003 Sep;37(9):919-29
pubmed: 14669999
Pharmacol Biochem Behav. 2012 Feb;100(4):752-74
pubmed: 21569789
Eur Neuropsychopharmacol. 2006 Aug;16(6):417-28
pubmed: 16376525
Behav Pharmacol. 2012 Apr;23(2):119-25
pubmed: 22198322
Pediatr Res. 2006 May;59(5):684-9
pubmed: 16627882
Nutr Neurosci. 2002 Feb;5(1):43-52
pubmed: 11929197
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):568-75
pubmed: 18060675
Mol Neurobiol. 2001 Aug-Dec;24(1-3):107-29
pubmed: 11831548
J Neuroinflammation. 2013 Apr 01;10:43
pubmed: 23547920
Eur Neuropsychopharmacol. 2013 Nov;23(11):1645-55
pubmed: 23622958
Psychol Med. 2013 May;43(5):897-910
pubmed: 22781489
Neuropsychopharmacology. 2010 Jan;35(1):105-35
pubmed: 19693004
Zebrafish. 2014 Aug;11(4):365-70
pubmed: 24979594
J Am Acad Child Adolesc Psychiatry. 2013 Mar;52(3):231-40
pubmed: 23452680
Cell Mol Neurobiol. 2013 Aug;33(6):825-35
pubmed: 23801192
J Clin Psychiatry. 2009 Aug;70(8):1128-37
pubmed: 19689920
Psychiatry Res. 2008 May 30;159(1-2):95-100
pubmed: 18339429
Behav Brain Res. 2017 Jan 15;317:461-469
pubmed: 27725170
J Clin Med. 2016 Jul 27;5(8):null
pubmed: 27472373
Eur Neuropsychopharmacol. 2006 Feb;16(2):93-100
pubmed: 16249073
Psychiatry Res. 2015 Dec 30;230(3):806-10
pubmed: 26564548
CNS Spectr. 2004 Oct;9(10):740-52
pubmed: 15448585
J Pharmacol Exp Ther. 2003 Sep;306(3):954-64
pubmed: 12750432
Exp Neurol. 2012 Jan;233(1):333-41
pubmed: 22079587
Front Behav Neurosci. 2015 Dec 14;9:343
pubmed: 26696857
J Clin Psychiatry. 2015 Aug;76(8):e1015-22
pubmed: 26335087
Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):363-6
pubmed: 19272303
J Clin Psychopharmacol. 2015 Aug;35(4):486-9
pubmed: 26066338
Int Clin Psychopharmacol. 2002 Sep;17(5):239-47
pubmed: 12177586
Nature. 2005 Dec 1;438(7068):662-6
pubmed: 16244648
Mol Nutr Food Res. 2013 Jun;57(6):1110-4
pubmed: 23390041
J Psychiatr Res. 2013 Nov;47(11):1831-4
pubmed: 24011862
J Clin Psychiatry. 2014 Apr;75(4):362-8
pubmed: 24569045
Curr Neuropharmacol. 2014 Mar;12(2):120-39
pubmed: 24669207
Arch Gen Psychiatry. 2001 May;58(5):445-52
pubmed: 11343523
Am J Physiol Regul Integr Comp Physiol. 2002 Nov;283(5):R1263-74
pubmed: 12376421
Adv Protein Chem Struct Biol. 2012;88:1-25
pubmed: 22814704
Atherosclerosis. 2006 Apr;185(2):320-6
pubmed: 16005881
Behav Neurosci. 1996 Jun;110(3):492-502
pubmed: 8888995
J Psychosom Res. 2007 Jan;62(1):1-8
pubmed: 17188114
Curr Drug Discov Technol. 2013 Sep;10(3):245-53
pubmed: 21838664
Antiinflamm Antiallergy Agents Med Chem. 2013;12(3):223-8
pubmed: 23651231
Behav Brain Res. 2010 Apr 2;208(2):545-52
pubmed: 20064565
Neurobiol Learn Mem. 2014 Dec;116:59-68
pubmed: 25180934
Stress. 2004 Mar;7(1):43-54
pubmed: 15204032
Brain Res. 2010 Nov 4;1359:178-85
pubmed: 20816762
J Clin Psychiatry. 2007 Nov;68(11):1723-32
pubmed: 18052566
Nat Rev Drug Discov. 2013 Sep;12(9):667-87
pubmed: 23989795
CNS Spectr. 2009 Jul;14(7):357-60
pubmed: 19773711
Curr Neuropharmacol. 2014 Mar;12(2):140-7
pubmed: 24669208
JAMA Psychiatry. 2016 May 1;73(5):490-6
pubmed: 27007062
Psychiatry Investig. 2013 Sep;10(3):281-5
pubmed: 24302952
Perit Dial Int. 2010 May-Jun;30(3):336-42
pubmed: 20190028
Burns. 2012 May;38(3):428-37
pubmed: 21978796
Pharmacol Rep. 2013;65(1):59-68
pubmed: 23563024
Nutr Neurosci. 2005 Aug;8(4):265-7
pubmed: 16491653
J Clin Psychopharmacol. 2014 Dec;34(6):772-4
pubmed: 25203471
Braz J Psychiatry. 2014 Jan-Mar;36(1):101
pubmed: 24604468
J Immunol. 1996 Aug 15;157(4):1630-7
pubmed: 8759749
Eur J Pharmacol. 2007 Jun 14;564(1-3):146-9
pubmed: 17395178
Inflamm Res. 2011 Jul;60(7):695-704
pubmed: 21424515
Complement Ther Med. 2013 Jun;21(3):141-6
pubmed: 23642943
J Clin Psychopharmacol. 2006 Dec;26(6):661-5
pubmed: 17110827
Life Sci. 1998;62(7):583-606
pubmed: 9472719
Clin Exp Immunol. 1993 Mar;91(3):456-61
pubmed: 8443968
Psychiatry Res. 2015 Sep 30;229(1-2):37-48
pubmed: 26296951
Neuropsychobiology. 2002;46(1):27-32
pubmed: 12207144
Behav Brain Res. 2011 May 16;219(1):116-22
pubmed: 21192985
Chronobiol Int. 2015 Mar;32(2):248-54
pubmed: 25286136
J Membr Biol. 2014 May;247(5):451-9
pubmed: 24682240
Pharmacol Biochem Behav. 2015 Dec;139 Pt B:121-6
pubmed: 26261019
Acta Anaesthesiol Scand. 2011 Sep;55(8):1015-21
pubmed: 22092168
Depress Anxiety. 2013 Apr;30(4):297-306
pubmed: 23468190
J Clin Psychopharmacol. 2012 Dec;32(6):797-803
pubmed: 23131885
Psychopharmacology (Berl). 2005 Feb;177(4):448-58
pubmed: 15289999
Trends Pharmacol Sci. 2005 Jan;26(1):27-35
pubmed: 15629202
Nat Rev Drug Discov. 2010 Aug;9(8):628-42
pubmed: 20577266
J Psychiatry Neurosci. 2011 Mar;36(2):78-86
pubmed: 21118657
Psychopharmacology (Berl). 2006 Jan;184(2):254-6
pubmed: 16374600
Adv Nutr. 2012 May 01;3(3):257-65
pubmed: 22585900
Pharmacol Biochem Behav. 2009 Nov;94(1):63-9
pubmed: 19635494
J Lipid Res. 2003 Oct;44(10):1984-91
pubmed: 12837849
Eur J Pharmacol. 2014 Jan 15;723:181-4
pubmed: 24361306
Brain Res. 2012 Jun 21;1461:111-8
pubmed: 22608068
J Neurosci Res. 2004 May 15;76(4):519-27
pubmed: 15114624
Eur Neuropsychopharmacol. 2006 Feb;16(2):107-13
pubmed: 16243493
Prostaglandins Leukot Essent Fatty Acids. 2009 Nov-Dec;81(5-6):309-12
pubmed: 19906519
Int J Neuropsychopharmacol. 2008 Sep;11(6):851-76
pubmed: 18205981
Psychiatr Clin North Am. 2013 Mar;36(1):15-23
pubmed: 23538073
Br J Dermatol. 2014 Nov;171(5):1253-5
pubmed: 24773206
J Clin Psychiatry. 2016 Nov;77(11):e1439-e1446
pubmed: 27736051
Cytokine. 1998 Apr;10(4):313-8
pubmed: 9617578
JAMA. 2017 Jul 18;318(3):235-236
pubmed: 28679009